IND Boot Camp |
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
|
Enduring |
|
$0.00 |
IIT- Protocol Amendments |
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
|
Enduring |
|
$0.00 |
Regulatory and Clinical Development Considerations for Chimeric Antigen Receptor (CAR) T Cells |
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
|
Enduring |
|
$0.00 |
Creating your Clinical Trial Protocol |
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
|
Enduring |
|
$0.00 |
Activation 201- What is the Role of the Activation PM |
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
|
Enduring |
|
$0.00 |
LCCC’s Single Subject Exception Policy |
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
|
Enduring |
|
$0.00 |
Everything a PI Needs to Know about LCCC as an IND Sponsor |
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
|
Enduring |
|
$0.00 |
IIT FDA Annual Reports |
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
|
Enduring |
|
$0.00 |
The "Tiny" Details that Can Wreak Havoc with a Protocol: Improve Protocol Development to Avoid Amendments |
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
|
Enduring |
|
$0.00 |
5 Tips for Developing and Maintaining an IND |
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
|
Enduring |
|
$0.00 |
Two Successful Clinical Trialists Reflect on How They Got Their Start |
|
Enduring |
|
$0.00 |
What is a “Critical Path” and How Can it Help Me? |
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
|
Enduring |
|
$0.00 |
Understanding when Assays become Investigational Assays |
|
Enduring |
|
$0.00 |
Gene Therapy- FDA and Local Considerations |
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
|
Enduring |
|
$0.00 |
IND Safety Reporting- LCCC IITs |
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
|
Enduring |
|
$0.00 |